Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma

被引：7

作者：

Lehmann, C

Wyen, C

Hoffmann, C

Fätkenheuer, G

机构：

[1] Univ Cologne, Dept Internal Med, D-5000 Cologne 41, Germany

[2] Univ Kiel, Dept Internal Med, D-24098 Kiel, Germany

来源：

HIV MEDICINE | 2005年 / 6卷 / 01期

关键词：

AIDS-associated non-Hodgkin's lymphoma; HAART; HIV; tuberculosis;

D O I：

10.1111/j.1468-1293.2005.00262.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Treatment of AIDS-related malignant lymphoma (ARL) remains a therapeutic challenge. There are concerns not only about infectious and haematological complications in HIV-infected patients during intensive chemotherapy, but also about potential interactions between chemotherapy and highly active antiretroviral therapy (HAART). Current data on patients treated concomitantly with intensive chemotherapy and HAART are limited, and no data exist on patients with ARL suffering from active opportunistic infections. We report the case of a 38-year-old man with advanced HIV-1 infection, pulmonary tuberculosis and Burkitt's lymphoma. Intensive chemotherapy was administered in parallel with tuberculostatic therapy and HAART. Six months later, the patient achieved not only a complete remission of Burkitt's lymphoma and sustained viral suppression, but also a full recovery from tuberculosis. This case report provides some useful observations on the successful application of intensive chemotherapy in addition to tuberculostatic therapy and HAART in HIV-infected patients.

引用

页码：51 / 53

页数：3

共 14 条

[1] Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy [J].

Antinori, A ;

Cingolani, A ;

Alba, L ;

Ammassari, A ;

Serraino, D ;

Ciancio, BC ;

Palmieri, F ;

De Luca, A ;

Larocca, LM ;

Ruco, L ;

Ippolito, G ;

Cauda, R .

AIDS, 2001, 15 (12) :1483-1491

[2] Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy [J].

Besson, C ;

Goubar, A ;

Gabarre, J ;

Rozenbaum, W ;

Pialoux, G ;

Châtelet, FP ;

Katlama, C ;

Charlotte, F ;

Dupont, B ;

Brousse, N ;

Huerre, M ;

Mikol, J ;

Camparo, P ;

Mokhtari, K ;

Tulliez, M ;

Salmon-Céron, D ;

Boué, F ;

Costagliola, D ;

Raphaël, M .

BLOOD, 2001, 98 (08) :2339-2344

[3] Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses [J].

Conti, S ;

Masocco, M ;

Pezzotti, P ;

Toccaceli, V ;

Vichi, M ;

Boros, S ;

Urciuoli, R ;

Valdarchi, C ;

Rezza, G .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (05) :451-458

[4] Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia [J].

Cortes, J ;

Thomas, D ;

Rios, A ;

Koller, C ;

O'Brien, S ;

Jeha, S ;

Faderl, S ;

Kantarjian, H .

CANCER, 2002, 94 (05) :1492-1499

[5] Improved outcome in adult B-cell acute lymphoblastic leukemia [J].

Hoelzer, D ;

Ludwig, WD ;

Thiel, E ;

Gassmann, W ;

Loffler, H ;

Fonatsch, C ;

Rieder, H ;

Heil, G ;

Heinze, B ;

Arnold, R ;

Hossfeld, D ;

Buchner, T ;

Koch, P ;

Freund, M ;

Hiddemann, W ;

Maschmeyer, G ;

Heyll, A ;

Aul, C ;

Faak, T ;

Kuse, R ;

Ittel, TH ;

Gramatzki, M ;

Diedrich, H ;

Kolbe, K ;

Fuhr, HG ;

Fischer, K ;

SchadeckGressel, C ;

Weiss, A ;

Strohscheer, I ;

Metzner, B ;

Fabry, U ;

Gokbuget, N ;

Volkers, B ;

Messerer, D ;

Uberla, K .

BLOOD, 1996, 87 (02) :495-508

[6] Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma [J].

Hoffmann, C ;

Wolf, E ;

Fätkenheuer, G ;

Buhk, T ;

Stoehr, A ;

Plettenberg, A ;

Stellbrink, HJ ;

Jaeger, H ;

Siebert, U ;

Horst, HA .

AIDS, 2003, 17 (10) :1521-1529

[7] Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology [J].

Little, RF ;

Pittaluga, S ;

Grant, N ;

Steinberg, SM ;

Kavlick, MF ;

Mitsuya, H ;

Franchini, G ;

Gutierrez, M ;

Raffeld, M ;

Jaffe, ES ;

Shearer, G ;

Yarchoan, R ;

Wilson, WH .

BLOOD, 2003, 101 (12) :4653-4659

[8] Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis [J].

Lopez-Cortes L.F. ;

Ruiz-Valderas R. ;

Pompyo V. ;

Aristides A.-G. ;

Gomez-Mateos J. ;

Leon-Jimenez E. ;

Sarasa-Nacenta M. ;

Lopez-Pua Y. ;

Pachon J. .

Clinical Pharmacokinetics, 2002, 41 (9) :681-690

[9] Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy [J].

Ratner, L ;

Lee, J ;

Tang, SH ;

Redden, D ;

Hamzeh, F ;

Herndier, B ;

Scadden, D ;

Kaplan, L ;

Ambinder, R ;

Levine, A ;

Harrington, W ;

Grochow, L ;

Flexner, C ;

Tan, B ;

Straus, D .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2171-2178

[10] Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV associated non-Hodgkin's lymphoma: An eastern cooperative oncology group trial (E1494) [J].

Sparano, JA ;

Lee, S ;

Chen, MG ;

Nazeer, T ;

Einzig, A ;

Ambinder, RF ;

Henry, DH ;

Manalo, J ;

Li, TH ;

Von Roenn, JH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1491-1500

← 1 2 →